A. Mark Schobel

A. Mark Schobel

Chief Innovation and Technology OfficeratAquestive Therapeutics· In proxies 2023–2024

Pay in FY2024+234% from the year before · Aquestive Therapeutics stock +76.2% the same year

A. Mark Schobel was paid $3.3M in FY2024 (Dec), up 234%. Aquestive Therapeutics stock rose 76.2% that year.

Pay$100 in the stock at the end of FY22 → $395
Pay is from the Summary Compensation Table of each Aquestive Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Aquestive TherapeuticsPublic company · 3 yr
    • Chief Innovation and Technology Officer2023 – Present · 3 yrStock in role +389%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?